We are excited to spotlight Dr. Tiejun Li, Vice General Manager of AsymBio, who will be presenting at the 16th Annual World ADC London on Feb 24, 2026 at 3:00 PM (ExCeL London). In his talk “Accelerating the Development of Next-Generation Bioconjugate Drugs Through an Integrated Platform,” Dr. Li will share insights on:• Key challenges in bioconjugation CMC development for novel NDCs• Case studies highlighting fit-for-purpose strategies for complex bioconjugation process development• AsymChem/AsymBio’s integrated capabilities in NDC CDMO services As a technology-driven global CDMO, AsymBio is committed to empowering innovators with robust, scalable, and regulatory-ready solutions across biologics and bioconjugates. If you are attending WorldADC2026, don't miss this session at ExCeL London - we look forward to connecting with you there!

Thrilled to share our highlights from the 2026 XDC & Antibody Drug Innovation Summit!The 2026 XDC & Antibody Drug Innovation Summit concluded successfully from January 6 to 7 at the DoubleTree by Hilton Hangzhou East Lake.As a trusted biologics CDMO, we showcased our next-gen ADC conjugation core technologies and one-stop platform solutions. Dr. Peng Qiang, Director of ADC Conjugation Process Development, delivered a standout keynote titled 《Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies》—diving into random/site-specific conjugation, process challenges, and scalable industrialization insights, backed by 10+ years of experience across 30+ global bioconjugate projects.Great connections with industry innovators, exploring ADC development trends and collaboration opportunities!MKT@asymchem.com.cnhttps://www.asymbio.com/

Thrilled to Join AET2025: Powering Biologics Innovation Together!What an inspiring week in San Diego! From AI-driven antibody discovery and next-gen bispecific/multispecific formats to novel ADC payload strategies and hands-on workshops focused on developability, every session highlighted the game-changing work shaping our industry. It was an honor to engage with leading academics, biotech innovators, and industry peers—diving deep into the challenges and opportunities that define antibody development today. Whether you're advancing a promising antibody program or seeking a trusted partner to navigate the complexities of development, we're here to support your journey. Email: MKT@asymchem.com.cn Website:https://www.asymbio.com/

What a rewarding experience connecting with global biotech peers, researchers, and industry leaders at the 16th Annual World ADC San Diego 2025! The dynamic discussions around ADC innovation—from targeted conjugate technologies to commercial production challenges—reaffirmed our commitment to empowering cutting-edge therapies.AsymBio provides comprehensive, end-to-end CDMO services tailored to your program needs—spanning R&D, process optimization, CMC, cGMP manufacturing.Whether you're advancing a first-in-class ADC or optimizing a biologics pipeline, AsymBio is here to turn your vision into clinical reality. Let's connect to explore how our trusted CDMO services can accelerate your journey:Email: MKT@asymchem.com.cnConnect to our experts：https://lnkd.in/gjw5yruHSee you at the next breakthrough—let's innovate together!

AsymBio team is heading to Antibody Engineering & Therapeutics in San Diego. Come and meet us at Booth #518! With industry leading CDMO solutions for antibodies, bioconjugates, etc., AsymBio is the partner of choice for your success.Connect with AsymBio at global leading antibody event for discovery, engineering and therapeutic development in neurodegeneration, metabolism, autoimmunity & much more!

A Major Milestone for AsymBio: Shanghai Fengxian Commercial Production Base Is Officially Operational!We are thrilled to announce the official launch of our Shanghai Fengxian Commercial Production Base - our third core commercial hub alongside Jinshan and Zhangjiang, marking a game-changing leap for our global biologics CDMO service network. Spanning 130,000+ square meters, this cutting-edge facility is built and verified for NDCs(including ADCs), antibodies/TCEs, and recombinant proteins.Key highlights for global partners: --Phase I-A (Antibody Capacity): Fully operational with 200L/500L/2000L single-use bioreactors and 20㎡ lyophilizers, ready to support IND and late-stage commercial projects.--Phase I-B (NDC Capacity): To be Launched in Jan 2026 with specialized conjugation reactors and multi-scale lyophilizers, delivering flexible, manufacturing solutions.--Compliance with NMPA, FDA, and EMA standards, ensuring seamless global market access for our partners.This is not just a new facility—it is our commitment to accelerating your path from innovation to patient impact. With scalable capacity and end-to-end CDMO capabilities, we're here to turn your groundbreaking biologics into life-changing therapies!

AsymBio is Thrilled to Join the 16th World ADC San Diego! Mark your calendars for Nov 3rd–6th, 2025. We will be at Booth #59 to showcase cutting-edge integrated solutions for your bioconjugates! Whether you’re tackling complex PD challenges or scaling up production, our experts are ready to collaborate and innovate with you. Don’t miss this chance to explore the future of ADC technology. Swing by our booth and let’s connect! Special Highlight: On Nov 4th, join Dr. Kai Gao, CTO of AsymBio, as he takes the stage in the Manufacturing Track. His presentation, “Development of Robust and Scalable Bioconjugation Processes for Next-We are excited to share knowledge, forge partnerships, and push the boundaries of what is possible in bioconjugates. See you in San Diego!

AsymBio is thrilled to join the 3rd ADC Process Development Summit in Boston—our first time at this industry-leading gathering focused on advancing antibody-drug conjugate (ADC) process innovation.Not only are we attending-we are proud to serve as a sponsor, too! This event is all about bringing together ADC and bioconjugate experts, and we can’t wait to connect with both new industry peers and longstanding partners who share our drive to elevate biotherapeutic development.Stop by to chat with our team and learn more about our end-to-end integrated solutions for bioconjugates (including ADCs)—from pre-clinical development and clinical advancement all the way to commercialization. Whether you’re tackling process challenges or exploring scalable pathways for your program, we’re here to share insights and support your goals.See you in Boston!

Basel. Connect with our experts and learn how our services can support your program at every stage!MeetAsymBio atFestival of BiologicsLocation: Messe and Congress Center BaselBooth: 235Dates: Sep 30-Oct 2, 2025

Radiopharm Theranostics (ASX: RAD, Nasdag: RADX＂Radiopharm＂ or the “Company＂), a clinical-stage biopharmaceutical company focused on developing innovative on cology radiopharmaceuticals for areas of high unmet medical need, announced that the U.S. food and Drug Administration (FDA) has provided clearance of the Company's Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4lg isoform of B7H3 that is highly expressed in tumors and not in healthy tissues.AsymBio, a strategic partner of Radiopharm Theranostics, extended its warm congratulations on the major milestone for Betabart (RV-01). The collaboration leveraged AsymBio’s industry-leading CDMO platform for Novel Drug Conjugates (NDCs) to complete CMC studies for IND submission. AsymBio looks forward to joint efforts with Radiopharm Theranostics to address critical unmet medical needs for patients worldwide.